ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Emcure completed the acquisition of a 12.05% stake in Gennova Biopharmaceuticals for ₹231.87 Crore, making it a wholly-owned subsidiary.
Emcure Pharmaceuticals acquires 12.05% minority stake in Gennova Biopharmaceuticals, making it a wholly-owned subsidiary. The move consolidates ownership to sharpen focus on biologics.
Emcure Pharmaceuticals will acquire a 12.05% stake in Gennova Biopharmaceuticals for Rs. 231.87 Crore. This transaction will make Gennova a wholly-owned subsidiary by July 2026.
Emcure's subsidiary, Gennova Biopharmaceuticals, will sell its mRNA business to Immunoscript Life Science for Rs. 139.5 Crore. The slump sale aligns with strategic business reorganization.
Emcure Pharmaceuticals announced acquisition of Mantra Pharma Inc. for Rs.336.3 Crore cash consideration. The deal expands Emcure’s footprint in the Canadian pharmaceutical market.
Emcure Pharma announced that its subsidiary Marcan will acquire Mantra Pharma for CAD $50 million (≈ ₹335 Crore). The acquisition makes Mantra a wholly‑owned step‑down subsidiary of Marcan.